A Clinical Evaluation of the Oxitone Non-invasive Oximeter (CPOM)

Clalit Health Services

Status

Unknown

Conditions

Chronic Lung Disease

COPD

Treatments

Device: Standard Oximeter

Device: Oxitone oximeter

Study type

Observational

Funder types

Other

Identifiers

NCT02658045

0172-15MMC

Details and patient eligibility

About

The trial shall assess the accuracy of the Oxitone® 1000 in measuring oxygen saturation, by comparing its measurement to reference devices: non-invasive SpO2 and pulse-rate values determined by a pulse oximeter. A total of approximately 40 subjects: 20 healthy and 20 COPD (chronic obstructive pulmonary disease ) patients will be enrolled. These subjects will be enrolled at the medical center pulmonary department and will be recruited from the clinic patient base. The subjects will be represented by male and female adults who optimally cover a range of ethnic backgrounds (skin pigmentation). All testing will be performed in singleton and in a blinded fashion. This study will be conducted with the approval of the medical center ethics committee.

This is a comparison open study with no subject follow-up.

Full description

The Oxitone® 1000 oximetry readings are accurate and measure with an acceptable relative absolute difference (RAD) when compared to accepted measurement systems (FDA recognized predicate) the "Reference".

The objectives:

To validate the Oxitone® 1000 performance in continuous or spot oximetry monitoring, relative to Reference readings.
To aggregate longitudinal clinical data from COPD patients measuring SpO2, pulse rate and activity.
To evaluate the main device parameters and characteristics such as sensor placement tolerance, device accuracy, precision, convenience and easy-to-use at stationary supine or seated tests and at mild motions as well.
To determine whether the measured data provided from patients (SpO2, pulse rate and movement) is useful in adjusting their treatment protocol.
To assess the safety and tolerability (compliance) of the Oxitone® 1000 in continuous oximetry monitoring in order to obtain sufficient clinical trial data in order to define performance criteria of the device system that are acceptable / useful in the medical context for patient populations and other healthy individuals, in which the device is likely to be used.

Overview: The trial shall assess the accuracy of the Oxitone® 1000 in measuring oxygen saturation, by comparing its measurement to reference devices: non-invasive SpO2 and pulse-rate values determined by a pulse oximeter. A total of approximately 40 subjects (20 healthy and 20 COPD patients) will be enrolled. These subjects will be enrolled at the medical center pulmonary department and will be recruited from the clinic patient base. The subjects will be represented by male and female adults who optimally cover a range of ethnic backgrounds (skin pigmentation). All testing will be performed in singleton and in a blinded fashion. This study will be conducted with the approval of the medical center ethics committee.This is a comparison open study with no subject follow-up.

Procedure: All instruments will be checked for functionality and battery operational capacity, prior to subject attachment including the data collection system, i.e. the wireless (B.T.) connectivity to P.C. (synchronized bidirectional two channels).

The "Reference" oximeter device shall be set for averaging mode of 12 seconds. Two sensors will be placed simultaneously on the subjects: A standard SpO2 (reference) will be placed on the subject's index finger and the tested Oxitone® 1000 will be placed on the subject's wrist of the same hand.

Methods:: The investigators are to study approximately 40 subjects, both normal, i.e. comparison group and patients with a variety of pulmonary conditions that effect oxygen saturation. The investigators will compare the oxygen saturation of each subject as measured with Oxitone® 1000 device and with the oxygen saturation as measured with calibrated conventional FDA approved pulse oximeter (predicate). The "Reference". No treatment decision will be made utilizing the results of the tested device.

Trial design:

A. Healthy subjects: Spot-check measurements of 20 healthy volunteers simultaneously tested by using Oxitone oximeter and standard fingertip pulse oximeter at stationary state i.e. at sitting and standing positions up to 6 minutes each.

A 6-minute.walk: oximetry tests of 20 healthy volunteers simultaneously tested using Oxitone oximeter and standard fingertip pulse oximeter in accordance with the industry (Medical) standards of 6-min walk protocol. Measurements are collected and recorded continuously prior to test, during the test and after 6 minutes the test. The distance of the 6-min walk will be recorded (CRF).

B. COPD (Chronic obstructive pulmonary disease) subjects

Spot-check measurements up to 20 ambulatory COPD patients. Patients should be referred and admitted to the pulmonary lab for clinical treatment or should be under the rehabilitation procedures. Measurements will be made simultaneously using Oxitone® oximeter and while standard fingertip pulse oximeter stationary state at e.g. supine or dorsal elevated sitting, and while standing (upright) positions up to 6 min each.
A 6-min walk oximetry tests of ambulatory COPD patients. Patients should be referred to the pulmonary lab for clinical purposes or should be under the rehabilitation procedures. The measurements are taken using Oxitone® oximeter and standard fingertip pulse oximeter in accordance with the standard protocol. Measurements are taken continuously prior to the test, during the test and 1 minute after the test, at rest. The distance of the 6-min walk will be recorded. Rehabilitation subjects procedures. The measurements are taken using Oxitone® Oximeter and standard fingertip pulse oximeter in accordance with the standard protocol. Measurements are taken continuously prior to the test. The distance of the 6-min walk will be recorded.

Enrollment

40 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Pulmonary sick and healthy male and female volunteers aged 18 years and over (any race or ethnicity).
Subjects who are willing to give informed consent.
No precautions are required: this study involves no known additional risk to the subjects.

Exclusion criteria